Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

Author(s):

James K. McCloskey, MD, John Theurer Cancer Center,Thomas W. LeBlanc, MD, MA

Panelists discuss how they approach luspatercept dosing strategies in clinical practice; manage treatment-related adverse events such as fatigue, hypertension, and diarrhea; and monitor labs for signs of relapse, while also considering real-world dose escalation outcomes and the correlation between peripheral blood and bone marrow biopsy mutations in patients with MDS.

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

Now Viewing

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

Video content above is prompted by the following:

What is your dosing strategy for luspatercept in your clinical practice?
Please comment on Patel K, et al. Real-world luspatercept dose escalation and outcomes. EHA 2024 abstract.
Please describe some potential treatment-related adverse events associated with luspatercept that you’ve observed in your clinical practice.
How do you manage fatigue, hypertension, and diarrhea?
What labs do you monitor and recheck for if you are concerned that this patient is relapsing?
Resource links: DeZern AE, et al. Correlation between PB and BMBx mutations from national MDS study. ASH 2023 abstract.